GDMT – Medxy AI

Right Ventricular to Pulmonary Artery Coupling: A New Prognostic Marker in Heart Failure Therapy

By MedXY 04/22/2026

A study reveals that RV-PA coupling, measured by TAPSE/sPAP ratio, significantly predicts outcomes in HFrEF patients during GDMT up-titration, highlighting its potential as a treatment target.

Cardiology news

Only 1 in 5 Veterans with Heart Failure Achieve Recommended Quadruple Therapy Within 3 Years—What This Means for Clinical Practice

By MedXY 04/05/2026

A large retrospective study of 52,850 veterans reveals that just 21.2% achieve guideline-directed quadruple therapy for HFrEF, with a median time of 197 days. Socioeconomic barriers, including prescription copays, emerge as critical modifiable factors hindering optimal treatment uptake.

Cardiology Clinical Updates news

Residual Clinical Risk and Economic Burden in HFrEF: Insights from the Quadruple Medical Therapy Era

By MedXY 03/14/2026

This review analyzes the real-world one-year outcomes and healthcare costs for HFrEF patients on quadruple therapy, revealing significant residual risk despite optimized pharmacologic management.